Enzalutamide in Metastatic Hormone Sensitive Prostate CancerLatest news for prostate cancer from the ASCO 2019 conference concluded few days ago:
Based on the publication and presentation of the ENZAMET trial, enzalutamide was associated with significantly longer progression-free and overall survival than standard care in men with metastatic, hormone-sensitive prostate cancer.
Enzalutamide would probably be approved for metastatic hormone sensitive (castrate sensitive) prostate cancer by the year end in my predictions, increasing the number of targetted therapies and chemotherapy in the already crowded treatment armamentarium of advanced prostate cancer.
https://www.nejm.org/doi/full/10.1056/NEJMoa1903835
Dr Rajeentheran Suntheralingam
7th June 2019
Source:
Enzalutamide in Metastatic Hormone Sensitive Prostate Cancer
